RARE Ultragenyx Pharmaceutical Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1515673 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.2%
TTM net income YoY-0.9%
TTM EPS YoY7.3%
Revenue 3-yr CAGR22.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-79.5%
Net margin-85.3%
FCF margin-70.1%
EBITDA margin-74.3%
Returns
ROE-656.6%
ROA-37.9%
ROIC (approx.)—
Asset turnover0.44x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio2.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $673.00M | $560.00M | $434.00M | $363.33M | $351.41M |
| R&D expense | $750.00M | $698.00M | $648.00M | $705.79M | $497.15M |
| SG&A expense | $349.00M | $321.00M | $310.00M | $278.14M | $219.98M |
| Operating income | -$535.00M | -$536.00M | -$569.00M | -$648.92M | -$381.74M |
| Pretax income | -$571.00M | -$567.00M | -$609.00M | -$701.73M | -$452.98M |
| Income tax | $4.00M | $2.00M | -$2.00M | $5.70M | $1.04M |
| Net income | -$575.00M | -$569.00M | -$607.00M | -$707.42M | -$454.02M |
| EBITDA | -$500.00M | -$500.00M | -$543.00M | -$630.70M | -$368.50M |
| EPS (basic) | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 |
| EPS (diluted) | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 |
| Weighted avg. shares (diluted) | 98.60M | 90.50M | 73.50M | 69.91M | 67.80M |
| Balance sheet | |||||
| Cash & equivalents | $421.00M | $174.00M | $214.00M | $132.94M | $307.58M |
| Short-term investments | $259.00M | $436.00M | $363.62M | $614.82M | $432.61M |
| Receivables | $158.00M | $122.00M | $73.39M | $40.45M | $28.43M |
| Inventory | $52.00M | $45.00M | $33.97M | $26.77M | $16.23M |
| Current assets | $951.00M | $817.00M | $732.18M | $883.90M | $856.60M |
| PP&E, net | $244.00M | $266.00M | $290.57M | $259.73M | $141.25M |
| Goodwill | $44.00M | $44.00M | $44.41M | $44.41M | $44.41M |
| Intangibles | $176.00M | $178.00M | $166.27M | $160.10M | $130.79M |
| Total assets | $1.53B | $1.50B | $1.49B | $1.55B | $1.52B |
| Current liabilities | $384.00M | $344.00M | $280.44M | $261.21M | $181.37M |
| Total liabilities | $1.60B | $1.24B | $1.22B | $1.19B | $599.84M |
| Shareholders' equity | -$80.00M | $255.00M | $275.00M | $352.00M | $922.56M |
| Shares outstanding | 96.60M | 92.50M | 82.32M | 70.20M | 69.34M |
| Cash flow statement | |||||
| Operating cash flow | -$466.00M | -$414.00M | -$475.00M | -$380.46M | -$338.69M |
| Capital expenditure | $6.00M | $7.00M | $44.00M | $116.12M | $73.09M |
| Free cash flow | -$472.00M | -$421.00M | -$519.00M | -$496.59M | -$411.79M |
| Investing cash flow | $236.00M | -$18.00M | $168.00M | -$291.65M | -$195.37M |
| Financing cash flow | $478.00M | $399.00M | $388.00M | $501.21M | $118.55M |
| Depreciation & amortization | $35.00M | $36.00M | $26.00M | $18.22M | $13.24M |
| Stock-based compensation | $153.00M | $158.00M | $135.00M | $130.37M | $104.98M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.